Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Autor:	Cheng Cheng, Raul C. Ribeiro, Francisco Pedrosa, Marcia Pedrosa, Ester Vinhas, Elaine Coustan-Smith, Alessandra Maria de Luna Ramos, Arli Pedrosa, Norma Lucena-Silva, Gaston K. Rivera, Yinmei Zhou, Dario Campana, Mecneide Mendes Lins
Rok vydání:	2020
Předmět:	Male medicine.medical_specialty Vincristine Neoplasm Residual Adolescent Cyclophosphamide Immunology Pilot Projects Neutropenia Biochemistry Gastroenterology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Asparaginase Humans Child Survival rate Dose-Response Relationship Drug Mercaptopurine business.industry Daunorubicin Cytarabine Infant Cell Biology Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis medicine.disease Minimal residual disease Survival Rate Regimen Leukemia Methotrexate Child Preschool Prednisone Female business Follow-Up Studies medicine.drug
Zdroj:	Blood. 135:1458-1466
ISSN:	1528-0020 0006-4971
Popis:	Treatment-related mortality is common among children with acute lymphoblastic leukemia (ALL) treated in poor-resource settings. We applied a simplified flow cytometric assay to identify patients with precursor B-cell ALL (B-ALL) at very low risk (VLR) of relapse and treated them with a reduced-intensity treatment plan (RELLA05). VLR criteria include favorable presenting features (age ≥ 1 and < 10 years), white blood cell count of
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f02a2ff17743ebf2d3be7da78e73eaa https://doi.org/10.1182/blood.2019004215 Zobrazit plný text záznamu